⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Akeso, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Akeso, Inc.
↗Guangdong, China
Akeso is a leading innovative biopharmaceutical company headquartered in China, focused on the research, development, manufacturing, and commercialization of first-in-class and best-in-class innovative biological medicines. The company has established a robust R&D ecosystem centered on proprietary platforms, including Tetrabody (bispecific antibody), Dual-Shield ADC, Dual-Lock T-cell engager (TCE), and Tissue-Smart siRNA/mRNA technologies.
Since its founding in 2012, Akeso has built a diverse pipeline of over 50 innovative assets targeting cancer, autoimmune diseases, inflammation, and metabolic diseases. The company is globally recognized for its bispecific antibody expertise, most notably ivonescimab (a PD-1/VEGF bispecific), which has demonstrated significant clinical efficacy and is the subject of a major international partnership with Summit Therapeutics.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Founded:2012
Ownership:public
Status:operating
STOCK
Exchange:HKEX
Ticker:9926.HK
Market Cap:$15B+
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:mAb, Bispecific antibody, ADC, siRNA/mRNA, Cell therapy
Active Trials:150
Trial Phases:Phase 3: 29
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Summit Therapeutics (Ivonescimab licensing for US, Canada, Europe, Japan, etc.), Pfizer (Collaboration on ivonescimab combination studies)
COMPETITION
Position:Leader
Competitors:BeiGene, Junshi Biosciences, Innovent Biologics, Henlius, Merck, Bristol Myers Squibb
LEADERSHIP
Key Executives:
Michelle Xia - Founder, Chairwoman, President, and CEO
LINKS
Website:akesobio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Akeso, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.